ReP USP - Resultado da busca

Artigo de periodico
Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo (2021)
Dominguez-Meijide, Antonio; Parrales, Valeria; Vasili, Eftychia; González-Lizárraga, Florencia; König, Annekatrin; Lázaro, Diana F.; Lannuzel, Annie; Haik, Stéphane; Guimarães, Elaine Aparecida Del Bel Belluz ; Chehín, Rosana; Raisman-Vozari, Rita; Michel, Patrick P.; Bizat, Nicolas; Outeiro, Tiago Fleming
Fonte: Neurobiology of Disease. Unidade: FORP
Assuntos: CAENORHABDITIS, LINHAGEM CELULAR, DOENÇAS NEURODEGENERATIVAS, DOENÇA DE PARKINSON
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOMINGUEZ-MEIJIDE, Antonio et al. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo. Neurobiology of Disease, v. 151, p. 1-19, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.nbd.2021.105256. Acesso em: 18 nov. 2024.
APA
Dominguez-Meijide, A., Parrales, V., Vasili, E., González-Lizárraga, F., König, A., Lázaro, D. F., et al. (2021). Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo. Neurobiology of Disease, 151, 1-19. doi:10.1016/j.nbd.2021.105256
NLM
Dominguez-Meijide A, Parrales V, Vasili E, González-Lizárraga F, König A, Lázaro DF, Lannuzel A, Haik S, Guimarães EADBB, Chehín R, Raisman-Vozari R, Michel PP, Bizat N, Outeiro TF. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo [Internet]. Neurobiology of Disease. 2021 ; 151 1-19.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.nbd.2021.105256
Vancouver
Dominguez-Meijide A, Parrales V, Vasili E, González-Lizárraga F, König A, Lázaro DF, Lannuzel A, Haik S, Guimarães EADBB, Chehín R, Raisman-Vozari R, Michel PP, Bizat N, Outeiro TF. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo [Internet]. Neurobiology of Disease. 2021 ; 151 1-19.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.nbd.2021.105256
Artigo de periodico
The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress (2021)
Ferreira Junior, Nilson Carlos; Pereira, Maurício dos Santos ; Francis, Nour; Ramirez, Paola; Martorell, Paula; González-Lizarraga, Florencia; Figadère, Bruno; Chehin, Rosana; Del Bel, Elaine Aparecida ; Raisman-Vozari, Rita; Michel, Patrick Pierre
Fonte: Cells. Unidade: FORP
Assuntos: ESTRESSE OXIDATIVO, GLICOSE, METABOLISMO, ANTIBIÓTICOS, AGENTES ANTIMICROBIANOS, FARMACOLOGIA EXPERIMENTAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA JUNIOR, Nilson Carlos et al. The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress. Cells, v. 10, n. 8, p. 1-16, 2021Tradução . . Disponível em: https://doi.org/10.3390/cells10082163. Acesso em: 18 nov. 2024.
APA
Ferreira Junior, N. C., Pereira, M. dos S., Francis, N., Ramirez, P., Martorell, P., González-Lizarraga, F., et al. (2021). The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress. Cells, 10( 8), 1-16. doi:10.3390/cells10082163
NLM
Ferreira Junior NC, Pereira M dos S, Francis N, Ramirez P, Martorell P, González-Lizarraga F, Figadère B, Chehin R, Del Bel EA, Raisman-Vozari R, Michel PP. The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress [Internet]. Cells. 2021 ; 10( 8): 1-16.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/cells10082163
Vancouver
Ferreira Junior NC, Pereira M dos S, Francis N, Ramirez P, Martorell P, González-Lizarraga F, Figadère B, Chehin R, Del Bel EA, Raisman-Vozari R, Michel PP. The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress [Internet]. Cells. 2021 ; 10( 8): 1-16.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3390/cells10082163
Artigo de periodico
Doxycycline interferes with tau aggregation and reduces its neuronal toxicity (2021)
Medina, Luciana; González-Lizárraga, Florencia; Dominguez-Meijide, Antonio; Ploper, Diego; Parrales, Valeria; Sequeira, Sabrina; Cima-Omori, Maria-Sol; Zweckstetter, Markus; Guimarães, Elaine Aparecida Del Bel Belluz ; Michel, Patrick P.; Outeiro, Tiago Fleming; Raisman-Vozari, Rita; Chehín, Rosana; Socias, Sergio B.
Fonte: Frontiers in Aging Neuroscience. Unidade: FORP
Assuntos: DOENÇA DE ALZHEIMER, ANTIBIÓTICOS, DOENÇAS NEURODEGENERATIVAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEDINA, Luciana et al. Doxycycline interferes with tau aggregation and reduces its neuronal toxicity. Frontiers in Aging Neuroscience, v. 13, p. 1-13, 2021Tradução . . Disponível em: https://doi.org/10.3389/fnagi.2021.635760. Acesso em: 18 nov. 2024.
APA
Medina, L., González-Lizárraga, F., Dominguez-Meijide, A., Ploper, D., Parrales, V., Sequeira, S., et al. (2021). Doxycycline interferes with tau aggregation and reduces its neuronal toxicity. Frontiers in Aging Neuroscience, 13, 1-13. doi:10.3389/fnagi.2021.635760
NLM
Medina L, González-Lizárraga F, Dominguez-Meijide A, Ploper D, Parrales V, Sequeira S, Cima-Omori M-S, Zweckstetter M, Guimarães EADBB, Michel PP, Outeiro TF, Raisman-Vozari R, Chehín R, Socias SB. Doxycycline interferes with tau aggregation and reduces its neuronal toxicity [Internet]. Frontiers in Aging Neuroscience. 2021 ; 13 1-13.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fnagi.2021.635760
Vancouver
Medina L, González-Lizárraga F, Dominguez-Meijide A, Ploper D, Parrales V, Sequeira S, Cima-Omori M-S, Zweckstetter M, Guimarães EADBB, Michel PP, Outeiro TF, Raisman-Vozari R, Chehín R, Socias SB. Doxycycline interferes with tau aggregation and reduces its neuronal toxicity [Internet]. Frontiers in Aging Neuroscience. 2021 ; 13 1-13.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fnagi.2021.635760
Artigo de periodico
Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease (2021)
Pereira, Maurício dos Santos ; Abreu, Gabriel Henrique Dias; Rocca, Jeremy; Hamadat, Sabah; Raisman-Vozari, Rita; Michel, Patrick Pierre; Del Bel, Elaine Aparecida
Fonte: Frontiers in Pharmacology. Unidade: FORP
Assuntos: ASTROCITOMA, CANABINOIDES, GLUTAMATOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA, Maurício dos Santos et al. Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease. Frontiers in Pharmacology, v. 11, p. 1-16, 2021Tradução . . Disponível em: https://doi.org/10.3389/fphar.2020.617085. Acesso em: 18 nov. 2024.
APA
Pereira, M. dos S., Abreu, G. H. D., Rocca, J., Hamadat, S., Raisman-Vozari, R., Michel, P. P., & Del Bel, E. A. (2021). Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease. Frontiers in Pharmacology, 11, 1-16. doi:10.3389/fphar.2020.617085
NLM
Pereira M dos S, Abreu GHD, Rocca J, Hamadat S, Raisman-Vozari R, Michel PP, Del Bel EA. Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease [Internet]. Frontiers in Pharmacology. 2021 ; 11 1-16.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fphar.2020.617085
Vancouver
Pereira M dos S, Abreu GHD, Rocca J, Hamadat S, Raisman-Vozari R, Michel PP, Del Bel EA. Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease [Internet]. Frontiers in Pharmacology. 2021 ; 11 1-16.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fphar.2020.617085

Unidades USP

ReP

Filtros

Autores

Assuntos

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada